(2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yl)oxy-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-1-[(2S)-2-[(1-hydroxy-3H-2,1-benzoxaborol-4-yl)carbamoylamino]-3,3-dimethylbutanoyl]pyrrolidine-2-carboxamide | 1285533-15-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yl)oxy-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-1-[(2S)-2-[(1-hydroxy-3H-2,1-benzoxaborol-4-yl)carbamoylamino]-3,3-dimethylbutanoyl]pyrrolidine-2-carboxamide
• CAS: 1285533-15-4
• 化学式: C₃₈H₄₄BClN₆O₁₀S
• 分子量: 823.132
• InChiKey: PQLHXHFBUVPBNZ-BWNUVLFESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.37
• 重原子数：
  57
• 可旋转键数：
  13
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  223
• 氢给体数：
  5
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  Asunaprevir; (1R,2S)-N-[(1,1-二甲基乙氧基)羰基]-3-甲基-L-缬氨酰-(4R)-4-[(7-氯-4-甲氧基-1-异喹啉基)氧基]-L-脯氨酰-1-氨基-N-(环丙基磺酰基)-2-乙烯基环丙基甲酰胺 在 盐酸 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 5.0h， 生成 (2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yl)oxy-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-1-[(2S)-2-[(1-hydroxy-3H-2,1-benzoxaborol-4-yl)carbamoylamino]-3,3-dimethylbutanoyl]pyrrolidine-2-carboxamide
  参考文献：
  名称：

  Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties

  摘要：

  We have synthesized and evaluated a new series of acyclic P4-benzoxaborole-based HCV NS3 protease inhibitors. Structure-activity relationships were investigated, leading to the identification of compounds 5g and 17 with low nanomolar potency in the enzymatic and cell-based replicon assay. The linker-truncated compound 5j was found to exhibit improved absorption and oral bioavailability in rats, suggesting that further reduction of molecular weight and polar surface area could result in improved drug-like properties of this novel series. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.006

文献信息

• Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties
  作者：Xianfeng Li、Suoming Zhang、Yong-Kang Zhang、Yang Liu、Charles Z. Ding、Yasheen Zhou、Jacob J. Plattner、Stephen J. Baker、Wei Bu、Liang Liu、Wieslaw M. Kazmierski、Maosheng Duan、Richard M. Grimes、Lois L. Wright、Gary K. Smith、Richard L. Jarvest、Jing-Jing Ji、Joel P. Cooper、Matthew D. Tallant、Renae M. Crosby、Katrina Creech、Zhi-Jie Ni、Wuxin Zou、Jon Wright

  DOI：10.1016/j.bmcl.2011.02.006

  日期：2011.4

  We have synthesized and evaluated a new series of acyclic P4-benzoxaborole-based HCV NS3 protease inhibitors. Structure-activity relationships were investigated, leading to the identification of compounds 5g and 17 with low nanomolar potency in the enzymatic and cell-based replicon assay. The linker-truncated compound 5j was found to exhibit improved absorption and oral bioavailability in rats, suggesting that further reduction of molecular weight and polar surface area could result in improved drug-like properties of this novel series. (C) 2011 Elsevier Ltd. All rights reserved.